U.S. Asthma Therapies Markets Growing Penetration of Combination Drugs Spur Growth

1
U.S. Asthma Therapies MarketsGrowing
Penetration of Combination Drugs Spur Growth

• The tremendous success of bronchodilator/-cortico
  steroid combination drugs will continue to drive
  growth in the asthma market, leaving single-agent
  therapies with limited growth opportunities to
  exploit throughout the forecast period

Pharmaceutical Biotech Analyst Team Frost
Sullivan
2
Industry Trends

• Growing Patient Penetration of Combination Drugs
• Growing Acceptance of Dry Powder Inhaler Delivery
  Systems
• Development of Innovative Pulmonary Delivery
  Systems

3
Key Features

• Frost Sullivan provides
• Detailed insights into recent developments and
  trends
• Drivers, restraints, challenges, and strategic
  recommendations
• Analyst insights on hot topics and emerging
  applications
• in the U.S. Asthma Therapies Markets
• Market sizing and competitive analysis
• Market forecasts and market share analysis
• Pricing analysis
• Product, vendor and end user analysis

4
What We Offer

• Coverage The United States
• Proven methodology encompassing extensive primary
  and secondary data and research
• Focused information and strategies that cover
  business and technology issues
• Credible data and analysis highlighting industry
  dynamics
• Winning strategies to help you create precise
  business plans

5
Who Will Benefit?

• Current Market Participants
• Find out how you compare to the competition
• Assess current and future drivers and restraints
• Determine and exploit new market share
  opportunities
• New Entrants
• Analyze challenges associated with the industry
• Calculate time scales for strategy implementation
• Position yourself to capitalize on the markets
  unmet needs
• Investment Community
• Analyze long-term strategies of companies in the
  asthma therapies markets
• Determine which participants will outperform the
  competition
• Assess attractiveness of investing in the asthma
  therapies markets

6
Whats Included

• Bronchodilators, subdivided into
• Short-Acting Beta2 Agonists
• Long-Acting Beta2 Agonists
• Anticholinergics
• Methylxanthines
• Anti-Inflammatories, subdivided into
• Inhaled Corticosteroids
• Anti-Leukotrienes
• Mediator-Release Inhibitors
• Other Emerging Anti-Inflammatory Therapeutics
• Bronchodilator/Corticosteroid Combinations
• Other Emerging Asthma Therapies

7
Key Market Participants
Ivax Pharmaceuticals, Inc. King Pharmaceuticals,
Inc. Merck Co., Inc. Morton Grove
Pharmaceuticals Novartis Pharmaceuticals Purdue
Pharmaceuticals Roxane Laboratories Savage
Laboratories Schering-Plough Sepracor,
Inc. Sheffield Pharmaceuticals Teva
Pharmaceuticals UCB Pharma Wallace
Pharmaceuticals Warrick Pharmaceuticals
3M Pharmaceuticals aaiPharma Abbott
Laboratories Alpharma Apotex Corp. AstraZeneca
Pharmaceuticals Aventis Pharmaceuticals,
Inc. Boehringer Ingelheim Dey, Inc. Forest
Laboratories, Inc. GlaxoSmithKline Impax
Labs Inspire Pharmaceuticals Inwood
Pharmaceuticals
8
For More Information

• Call toll free 877 GO FROST
• (877.463.7876)
• Fax toll free 888.690.3329
• Email myfrost_at_frost.com
• Visit www.frost.com